Role of Stenotrophomonas maltophilia in hospital-acquired infection

British Journal of Biomedical Science

Volumn 62, Issue 3, 2005, Pages 145-154

  Looney, W J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bacterial infections; Drug resistance, bacterial; Intensive care; Stenotrophomonas maltophilia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CIPROFLOXACIN; CLAVULANIC ACID; CLINAFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOFILM; DRUG USE; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STENOTROPHOMONAS MALTOPHILIA;

BACTERIA (MICROORGANISMS); STENOTROPHOMONAS MALTOPHILIA;

EID: 27744502118     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2005.11732702     Document Type: Review

References (69)

1. Department of Health. Towards cleaner hospitals and lower rates of infection. DoH: London, July 2004.
2. Hanberger H, Diekema D, Fluit A et al. Surveillance of antibiotic resistance in European ICUs J Hosp Infect 2001; 48: 161-76.
3. Mehta RM, Niederman MS. Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med 2003; 18: 175-88.
4. Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections: the clinical challenges. J Hosp Infect 2003; 55: 1-12.
5. Gilligan PH, Lum G, Vandamme PAR, Whittier S. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea and Acidovorax In: Manual of clinical microbiology (8th edn). Washington: ASM Press, 2003: 729-48.
6. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45: 47-53.
7. Bywater RJ, Casewell MW. An assessment of the impact of antibiotic resistance in different bacterial species and of the contribution of animal sources to resistance in human infections J Antimicrob Chemother 2000; 46: 639-45.
8. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity and antibiotic resistance. Clin Microbiol Rev 2002; 15: 647-79.
9. Whitby PW, Carter KB, Burns JL, Royall JA, LiPuma JA, Stull TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol 2000; 38: 4305-9.
10. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30: 453-64.
11. Apisarnthanarak A, Fraser VJ, Dunne WM et al. Stenotrophomonas maltophilia intestinal colonisation in hospitalised oncology patients with diarrhea. Clin Infect Dis 2003; 37: 1131-5.
12. Morrison AJ, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24: 52-5.
13. Sattler CA, Mason EO, Kaplan SL. Non-respiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis 2000; 31: 1321-30.
14. Gilardi GL. Pseudomonas and related genera. In: Manual of clinical microbiology (5th edn). Washington: ASM Press, 1991: 429-41.
15. Klärner HG, Eschenbach U, Kamereck K, Lehn N, Wagner H, Miethke T. Failure of an automated blood culture system to detect non-fermentative Gram-negative bacteria. J Clin Microbiol 2000; 38: 1036-41.
16. Denton M, Hall MJ, Todd NJ, Kerr KG, Littlewood JM. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium. Clin Microbiol Infect 2000; 6: 385-95.
17. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002; 121: 1754-60.
18. O'Brien M, Davis GHG. Enzymatic profile of Pseudomonas maltophilia. J Clin Microbiol 1982; 16: 417-21.
19. Kataoka D, Fujiwara H, Kawakami T et al. The indirect pathogenicity of Stenotrophomonas maltophilia. Int J Antimicrob Agents 2003; 22: 601-6.
20. Barrow GI, RKA Feltham, eds. Cowin and Steel's Manual for the identification of medical bacteria. Cambridge: Cambridge University Press, 1993.
21. Döring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis 2004; 3: 67-91.
22. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Inject Dis 1995; 20: 445-8.
23. McMenamin JD, Zaccone TM, Coenye T, Vandamme P, LiPuma JJ. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 2000; 117: 1661-5.
24. Kiska DL, Kerr A, Jones MC et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other Gram-negative non-fermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34: 886-91.
25. Van Pelt C, Verduin CM, Goessens HF et al. Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol 1999; 37: 2158-64.
26. Rhoden DL, Schable B, Smith PB. Evaluation of PASCO MIC-ID system for identifying Gram-negative bacilli. J Clin Microbiol 1987; 25: 2363-6.
27. Otto LA, Blachman U. Non-fermentative bacilli: evaluation of three systems for identification. J Clin Microbiol 1979; 10: 147-54.
28. Valdezate S, Vindel A, Baquero F, Canton R. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 1999; 18: 908-11.
29. Stefaniuk E, Baraniak A, Gniadkowski M, Hryniewiez W. Evaluation of the BD Phoenix automated identification and susceptibility testing system in clinical microbiology laboratory practice. Eur J Clin Microbiol Infect Dis 2003; 22: 479-85.
30. Carroll KC, Cohen S, Nelson R et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diag Microbiol Infect Dis 1998; 32: 229-35.
31. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001; 48 (Suppl S1): 77-80.
32. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44: 287-93.
33. McKay GA, Woods DE, MacDonald KL, Poole K. Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence and antibiotic resistance. Infect Immun 2003; 71: 3068-75.
34. Li XZ, Zhang L, Poole K. SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2002; 46: 333-43.
35. Alonso A, Morales G, Escalante R, Campanario E, Sastre L, Martinez JL. Overexpression of the multidrug efflux pump SmeDEF impairs Stenotrophomonas maltophilia physiology. J Antimicrob Chemother 2004; 53: 432-4.
36. Li XZ, Zhang L, McKay GA, Poole K. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antibicrob Chemother 2003; 51: 803-11.
37. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother 1982; 22: 564-70.
38. Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennett PM. Differential regulation of L1 and L2 beta-lactamase expression in Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 49: 387-9.
39. Alonso A, Sanchez P, Martinez JL. Stenotrophomonas maltophilia D457R contains a cluster of genes from Gram-positive bacteria involved in antibiotic and heavy-metal resistance Antimicrob Agents Chemother 2000; 44: 1778-82.
40. Barbolla R, Catalane M, Orman BE et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates Antimicrob Agents Chemother 2004; 48: 666-9.
41. Chang LL, Chen HF, Chang CY, Lee TM, Wu WJ. Contribution of integrons, and SmeABC and SmeDEF efflux pumps, to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2004; 53: 518-21.
42. Travassos LH, Pinheiro MN, Coelho FS, Sampaio JLM, Merquior VLC, Marques EA. Phenotypic properties, drug susceptibility and genetic relatedness of Stenotrophomonas maltophilia clinical strains from seven hospitals in Rio de Janeiro, Brazil. J Appl Microbiol 2004; 96: 1143-50.
43. de Oliveira-Garcia D, Dall'Agnol M, Resales M et al. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol 2003; 5: 625-36.
44. Hanes SD, Demirkan K, Tolley E et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35: 228-35.
45. Platsouka E, Routsi C, Chalkis A, Dimitriadou E, Paniara O, Roussos C. Stenotrophomonas maltophilia meningitis, bacteraemia and respiratory infection. Scand J Infect Dis 2002; 34: 391-2.
46. Tsiodras S, Pittet D, Carmeli I, Eliopoulos G, Boucher H, Harbarth S Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32: 651-6
47. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999; 11: 28-33.
48. Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by Stenotrophomonas maltophilia: a prospective study. Infection 2001; 29: 205-8.
49. Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 2003; 31: 155-61.
50. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis Pediatr Pulmonol 2000; 30: 10-5
51. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 168-71.
52. Lanotte P, Cantagrel S, Mereghetti M et al. Spread of Stenotrophomonas maltophilia colonisation in a pediatric intensive care unit detected by monitoring tracheal bacterial carriage and molecular typing. Clin Microbiol Infect 2003; 9: 1142-7.
53. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobactcr species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2): 104-13.
54. Senol E, Desjardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Inject Dis 2002; 34: 1653-6.
55. Crispino M, Boccia MC, Bagattini M, Villari P, Triassi M, Zarrilli R. Molecular epidemiology of Stenotrophomonas maltophilia in a university hospital. J Hosp Infect 2002; 52: 88-92.
56. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35: 1281-307.
57. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 356-61.
58. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
59. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother 2001; 48: 152-4.
60. Weiss K, Restieri C, De Carolis E, Laverdière M, Guay H. Comparative acitivity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45: 363-5.
61. Communicable Disease Surveillance Centre. Antimicrobial resistance in 2000: England and Wales. www.hpa.org.uk/infections/topics_az/ antimicrobial_resistance/a mr.pdf.
62. Caylan R, Kaklikkaya N, Aydin K et al. An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital Jpn J Infect Dis 2004; 57: 37-40.
63. Saiman L. Microbiology of early CF lung disease. Pediat Respir Reviews 2004; 5(Suppl A): S367-S369.
64. Denton M, Rajgopal A, Mooney L et al. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 2003; 55: 180-3.
65. Laing FPY, Ramotar K, Read RR et al. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995; 33: 513-8.
66. Valdezate S, Vindel A, Martin-Davila P, Del Saz S, Baquero F, Canton R. High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol 2004; 42: 693-9.
67. Wishart MM, Riley TV. Infection with Pseudomonas maltophilia: hospital outbreak due to contaminated disinfectant. Med J Aust 1976; 19: 710-2.
68. Rogues AM, Maugein J, Allery A et al. Electronic ventilator temperature sensors as a potential source of respiratory tract colonisation with Stenotrophomonas maltophilia. J Hosp Infect 2001; 49: 289-92.
69. Lemmen SW, Häfner H, Kotterik S, Lütticken R, Töpper R. Influence of an infectious disease service on antibiotic prescription behaviour and selection of multiresistent pathogens. Infection 2000; 28: 384-7.